Whoops: CMS qui­et­ly pares back list of drugs re­quir­ing new re­bates un­der In­fla­tion Re­duc­tion Act

To dis­cour­age rapid drug price in­creas­es, the In­fla­tion Re­duc­tion Act re­quires phar­ma com­pa­nies that raise cer­tain drug prices faster than the rate of in­fla­tion to pay Medicare new re­bates, be­gin­ning in 2025.

But the ini­tial list of 27 drugs that would be hit with the re­bates, un­veiled March 15, was cut by about 25% late last week, with CMS now re­mov­ing sev­en of those drugs, in­clud­ing two from Gilead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER